{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:48:46Z","timestamp":1759340926029},"reference-count":24,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2020,2,20]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The inhibition of transient receptor potential vanilloid receptor 1\n(TRPV1) has emerged as a novel approach for the treatment of various pain states. Pyrrolidinyl\nurea, SB 705498 with pKb = 7.3 in guinea pig TRPV1 receptor has been investigated in Phase II\nclinical trials for pain and chronic cough. Another heteroaryl urea derivative, A-425619 1, has\nbeen reported to be a potent and selective TRPV1 antagonist of capsaicin-evoked receptor activation\nwith an IC50 value of 4 nM in hTRPV1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>A series of thirteen A-425619 1 analogues with modifications centered around the Cregion\nwere synthesized to understand the binding site characteristics of TRPV1 receptors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>We synthesized a series of isoquinoline ureas and evaluated their antagonist potency using\nsmooth muscle assay using guinea pig trachea along with the evaluation of the molecular properties\nand molecular modeling using CoMFA studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>p-Chloro 4, p-bromo 5, m-isothiocyanate 15, and p-isothiocyanate 16 derivatives were\nfound to be the most potent members of the series with pKb values in the range of 7.3-7.4 in the\nfunctional assay using guinea pig trachea. The lead compound A-425619 1 exhibited a pKb value\nof 8.1 in this assay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The para-substituted analogues were found to be more potent than the ortho- and\nmeta- analogues in the biological assay. This observation was further supported by molecular\nmodeling studies using CoMFA.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406415666190626130453","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T20:06:03Z","timestamp":1561579563000},"page":"202-211","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis, and Evaluation of Isoquinoline Ureas as TRPV1 Antagonists"],"prefix":"10.2174","volume":"16","author":[{"given":"Nehaben A.","family":"Gujarati","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Undem","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21224, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya L.","family":"Korlipara","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/35077544","volume":"2","author":"Clapham D.E.","year":"2001","unstructured":"Clapham D.E.; Runnels L.W.; Str\u00fcbing C.; The TRP ion channel family. Nat Rev Neurosci 2001,2(6),387-396","journal-title":"Nat Rev Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157015906775202995","volume":"4","author":"Messeguer A.","year":"2006","unstructured":"Messeguer A.; Planells-Cases R.; Ferrer-Montiel A.; Physiology and pharmacology of the vanilloid receptor. Curr Neuropharmacol 2006,4(1),1-15","journal-title":"Curr Neuropharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-642-54215-2_9","volume":"222","author":"Bevan S.","year":"2014","unstructured":"Bevan S.; Quallo T.; Andersson D.A.; Trpv1. Handb Exp Pharmacol 2014,222,207-245","journal-title":"Handb Exp Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1021\/jm060637e","volume":"50","author":"Westaway S.M.","year":"2007","unstructured":"Westaway S.M.; The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem 2007,50(11),2589-2596","journal-title":"J Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature02196","volume":"426","author":"Clapham D.E.","year":"2003","unstructured":"Clapham D.E.; TRP channels as cellular sensors. Nature 2003,426(6966),517-524","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/157488906775245309","volume":"1","author":"Roberts L.A.","year":"2006","unstructured":"Roberts L.A.; Connor M.; TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Patents CNS Drug Discov 2006,1(1),65-76","journal-title":"Recent Patents CNS Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.bmcl.2015.12.103","volume":"26","author":"Wolkerstorfer A.","year":"2016","unstructured":"Wolkerstorfer A.; Handler N.; Buschmann H.; New approaches to treating pain. Bioorg Med Chem Lett 2016,26(4),1103-1119","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=8","first-page":"443","volume":"52","author":"LeGay C.M.","year":"2017","unstructured":"LeGay C.M.; Derksen D.J.; Structure-Activity Relationship (SAR) Studies of Transient Receptor Potential (TRP). Channel Modulators Med Chem Rev 2017,52,443-463","journal-title":"Channel Modulators Med Chem Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1021\/jm00039a006","volume":"37","author":"Walpole C.S.J.","year":"1994","unstructured":"Walpole C.S.J.; Bevan S.; Bovermann G.; Boelsterli J.J.; Breckenridge R.; Davies J.W.; Hughes G.A.; James I.; Oberer L.; Winter J.; The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 1994,37(13),1942-1954","journal-title":"J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd2280","volume":"6","author":"Szallasi A.","year":"2007","unstructured":"Szallasi A.; Cortright D.N.; Blum C.A.; Eid S.R.; The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007,6(5),357-372","journal-title":"Nat Rev Drug Discov"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1016\/j.bmcl.2006.03.030","volume":"16","author":"Rami H.K.","year":"2006","unstructured":"Rami H.K.; Thompson M.; Stemp G.; Fell S.; Jerman J.C.; Stevens A.J.; Smart D.; Sargent B.; Sanderson D.; Randall A.D.; Gunthorpe M.J.; Davis J.B.; Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006,16(12),3287-3291","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/157340708785294235","volume":"4","author":"Korlipara V.L.","year":"2008","unstructured":"Korlipara V.L.; Transient receptor potential vanilloid 1 channel modulation: a novel approach to pain therapy. Curr Bioact Compd 2008,4,110-125","journal-title":"Curr Bioact Compd"},{"key":"ref=13","first-page":"3053","volume":"14","author":"Jetter M.C.","year":"2004","unstructured":"Jetter M.C.; Youngman M.A.; McNally J.J.; Zhang S-P.; Dubin A.E.; Nasser N.; Dax S.L.; N-isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1. Bioorg Med Chem Lett 2004,14(12),3053-3056","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bmcl.2004.01.041","volume":"14","author":"Park H-G.","year":"2004","unstructured":"Park H-G.; Choi J-Y.; Choi S-H.; Park M-K.; Lee J.; Suh Y-G.; Cho H.; Oh U.; Kim H-D.; Joo Y-H.; Lee J.; Kim S-Y.; Park Y-H.; Jeong Y.S.; Choi J.K.; Kim J.K.; Kang S-U.; Jew S-S.; N-4-Methansulfonamidobenzyl-N\u2032-2-substituted 4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett 2004,14,1693-1696","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1021\/jm070276i","volume":"50","author":"Perner R.J.","year":"2007","unstructured":"Perner R.J.; DiDomenico S.; Koenig J.R.; Gomtsyan A.; Bayburt E.K.; Schmidt R.G.; Drizin I.; Zheng G.Z.; Turner S.C.; Jinkerson T.; Brown B.S.; Keddy R.G.; Lukin K.; McDonald H.A.; Honore P.; Mikusa J.; Marsh K.C.; Wetter J.M.; George K.S.; Jarvis M.F.; Faltynek C.R.; Lee C.H.; \n                        In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists. J Med Chem 2007,50(15),3651-3660","journal-title":"J Med Chem"},{"key":"ref=16","year":"2018","unstructured":"ClinicalTrials.gov Identifier: NCT01424514. Available at 2018"},{"key":"ref=17","year":"2018","unstructured":"ClinicalTrials.gov Identifier: NCT01476098. Available at: 2018"},{"key":"ref=18","year":"2018","unstructured":"ClinicalTrials.gov Identifier: NCT01476098. Available at: 2018"},{"key":"ref=19","year":"2018","unstructured":"ClinicalTrials.gov Identifier: NCT01673529. Available at: 2018"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/jm0492958","volume":"48","author":"Gomtsyan A.","year":"2005","unstructured":"Gomtsyan A.; Bayburt E.K.; Schmidt R.G.; Zheng G.Z.; Perner R.J.; Didomenico S.; Koenig J.R.; Turner S.; Jinkerson T.; Drizin I.; Hannick S.M.; Macri B.S.; McDonald H.A.; Honore P.; Wismer C.T.; Marsh K.C.; Wetter J.; Stewart K.D.; Oie T.; Jarvis M.F.; Surowy C.S.; Faltynek C.R.; Lee C.H.; Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J Med Chem 2005,48(3),744-752","journal-title":"J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0040-4039(01)80041-1","volume":"25","author":"Bellamy F.D.","year":"1984","unstructured":"Bellamy F.D.; Ou K.; Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron Lett 1984,25,839-842","journal-title":"Tetrahedron Lett"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/jm00008a012","volume":"38","author":"Korlipara V.L.","year":"1995","unstructured":"Korlipara V.L.; Takemori A.E.; Portoghese P.S.; Electrophilic N-benzylnaltrindoles as \u03b4 opioid receptor-selective antagonists. J Med Chem 1995,38(8),1337-1343","journal-title":"J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1016\/j.bmc.2006.03.027","volume":"14","author":"Drizin I.","year":"2006","unstructured":"Drizin I.; Gomtsyan A.; Bayburt E.K.; Schmidt R.G.; Zheng G.Z.; Perner R.J.; DiDomenico S.; Koenig J.R.; Turner S.C.; Jinkerson T.K.; Brown B.S.; Keddy R.G.; McDonald H.A.; Honore P.; Wismer C.T.; Marsh K.C.; Wetter J.M.; Polakowski J.S.; Segreti J.A.; Jarvis M.F.; Faltynek C.R.; Lee C.H.; Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists. Bioorg Med Chem 2006,14(14),4740-4749","journal-title":"Bioorg Med Chem"},{"key":"ref=24","first-page":"85","volume":"268","author":"Ellis J.L.","year":"1994","unstructured":"Ellis J.L.; Undem B.J.; Inhibition by capsazepine of resiniferatoxin- and capsaicin-induced contractions of guinea pig trachea. J Pharmacol Exp Ther 1994,268(1),85-89","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T13:50:10Z","timestamp":1584021010000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173012\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406415666190626130453","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}